The findings suggest that reconsideration of current clinical guidelines, which support MRI only for symptomatic brain ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...